NOVEL THERAPY FOR PANCREATIC CANCERS, TARGETING MOLECULAR FOUNDATION
Dr Michael KC Lee,
Medical Oncologist,
Peter MacCallum Cancer Centre,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | February 2026
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
His care philosophy, embodied in his practice name, “Can-Therapy,” promotes a CAN-do approach to CANcer care: empowering patients to thrive beyond cancer through cutting-edge research and personalised, values-driven care. Beyond the clinic, he leads research as a clinician scientist, developing therapeutic strategies that target RNA processing – the molecular blueprint cancer hijacks to fuel its growth and resistance – by altering its sequence is like changing words in a sentence to redefine cancer’s trajectory.
Supported by Pancare Foundation, the Paul Dear Post Doctoral Fellowship and his industry collaboration, his work aims to revolutionise outcomes for patients with this aggressive cancer by targeting its molecular foundation.
He is a recognised expert in pancreatic cancer care, combining research insights with exceptional patient care, while also providing comprehensive treatment for all cancer types.
Source: Supplied
https://orcid.org/0000-0001-8075-3608
-
Dr Ryan O’Hare Doig
NEIL SACHSE CENTRE FOR SPINAL CORD RESEARCH (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA -
Vaccine effectiveness against infections triggering autoimmune disease
Dr Deborah Burnett is a Scientia Senior Lecturer and Laboratory Head at UNSW, where she leads a multidisciplinary research program spanning mechanistic immunology and translational vaccinology. Her work focuses on understanding how immune responses can protect against challenging infectious threats, including bacterial infections and infections associated with autoimmune disease.
-
Biomarkers for early sepsis detection
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
